The similar strong upregulation (to 189%, P=0.08) of the phospholipid transfer protein (PLTP) transcript was assessed, because PLTP modifies ataxia, Alzheimer's disease and tau phosphorylation and serves as lipopolysaccharide interactor (Dong et al., 2009; Gautier and Lagrost, 2011; Albers et al., 2012). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.